Regeneron Pharmaceuticals (REGN) Financials: Revenue & Earnings

REGN$904.35+1.45 +0.16%

$93.54B

Market Cap

19.42

P/E

11.31

Forward P/E

58

Score

AI Analysis

Snapshot

Regeneron Pharmaceuticals is a mixed profile at 58/100 — Value 52, Growth 52, Quality 69. Under the hood: P/E 19.8, plus revenue compounding ~6% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

52
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

52
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

69
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Regeneron Pharmaceuticals, Inc. (REGN) last printed $904.35. Equity value is $93.54B. Trailing earnings multiple 19.42. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$4.86B$5.87B$6.71B$6.56B$8.5B$16.07B$12.17B$13.12B$14.2B$14.34B

About

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Regeneron Pharmaceuticals (REGN) Financials: Revenue & Earnings

REGN price $904.35 +1.45 +0.16%

Ticker
REGN
Price
$904.35
Change
+1.45 +0.16%
Market cap ?
$93.54B
P/E ?
19.42
Forward P/E ?
11.31
Dividend yield ?
0.40%
Beta ?
0.24
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
58
Value
52
Quality
69
Growth
52

Stocklytics score rationale: value 52, quality 69, growth 52.

AI Score 85. Regeneron Pharmaceuticals, Inc. has a strong market cap of approximately $95.5 billion and impressive profit margins, with a net profit margin of 28.5%

Fair value

REGN fair value $1,660.22. Price $904.35. Price is 46% below fair value.

Below fair value, and cheaper than usual. A larger discount than on 64% of days in the past 5 years.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price.

Fair value blends a 10-year DCF and an earnings multiple: the average of the DCF value and an earnings value from next-twelve-months EPS times 23.6, a blend of the Biotechnology median (29.4) and the stock's own 10-year median (17.9). How we calculate it →

Compare REGN

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2027-01-28—25.39—5.85B
2026-10-3020.0716.515.12B4.58B
2026-07-3014.2910.164.29B3.82B
2026-04-299.478.913.61B3.48B
2026-01-3011.4410.743.88B3.81B
2025-10-2811.839.653.75B3.59B
2025-08-0112.898.433.68B3.29B
2025-04-298.228.623.03B3.25B
2025-02-0412.0711.213.79B3.74B
2024-10-3112.4611.693.72B3.67B
2024-08-0111.5610.613.55B3.38B
2024-05-029.5510.173.15B3.23B
2024-02-0211.8610.733.43B3.29B
2023-11-0211.5910.723.36B3.22B
2023-08-0310.249.843.16B3.02B
2023-05-0410.099.253.16B3.00B
2023-02-0312.5610.033.41B3.12B
2022-11-0311.149.482.94B2.92B
2022-08-039.778.532.86B2.79B
2022-05-048.939.742.97B2.69B
2022-02-0421.3218.354.95B4.56B
2021-11-0414.3710.103.45B2.69B
2021-08-0525.8017.535.14B3.92B
2021-05-069.899.002.53B2.65B
2021-02-059.538.392.42B2.46B
2020-11-058.367.142.29B301.49M
2020-08-057.165.981.95B1.63B
2020-05-056.606.131.83B1.70B
2020-02-067.506.912.17B2.00B
2019-11-056.676.362.05B1.95B
2019-08-066.025.421.93B1.42B
2019-05-074.455.471.71B1.69B
2019-02-066.845.601.93B1.58B
2018-11-065.875.131.66B1.45B
2018-08-025.454.701.61B1.39B
2018-05-034.674.351.51B1.41B
2018-02-085.234.681.58B1.37B
2017-11-083.993.851.50B1.45B
2017-08-034.173.171.47B1.12B
2017-05-042.923.061.32B1.38B

Dividends

Yield 0.41%. Payout ratio 7.95%. Frequency Quarterly.

Safety score 72/100 · Moderate. Payout ratio is 8% of earnings. Dividends use less than 40% of free cash flow. Dividend history is short. Yield is 0.4%, which is modest.

Ex-dateDividendRecordPaymentFrequency
2026-11-20$0.942026-11-202026-12-03Quarterly
2026-08-18$0.942026-08-182026-08-31Quarterly
2026-05-20$0.942026-05-202026-06-04Quarterly
2026-02-20$0.942026-02-202026-03-05Quarterly
2025-11-20$0.882025-11-202025-12-05Quarterly
2025-08-18$0.882025-08-182025-09-03Quarterly
2025-05-20$0.882025-05-202025-06-06Quarterly
2025-02-20$0.882025-02-202025-03-20Quarterly

Insider trades

DateInsiderActionSharesPriceValue
2026-11-04Pitofsky JasonBuy905$492.00445.26K
2026-11-04Pitofsky JasonSell439$939.57412.47K
2026-11-04Pitofsky JasonBuy1.48K$644.54952.63K
2026-11-04Pitofsky JasonSell575$940.46540.76K
2026-11-04Pitofsky JasonSell982$941.58924.63K
2026-11-04Pitofsky JasonBuy1.50K$726.531.09M
2026-11-04Pitofsky JasonSell1.22K$942.311.14M
2026-11-04Pitofsky JasonSell529$943.53499.13K
2026-11-04Pitofsky JasonSell108$944.22101.98K
2026-11-04Pitofsky JasonSell35$945.6133.10K
2026-11-04Pitofsky JasonSell1.50K$726.531.09M
2026-11-04Pitofsky JasonSell1.48K$644.54952.63K
2026-11-04Pitofsky JasonSell905$492.00445.26K
2026-11-04Pitofsky JasonSell179$950.76170.19K
2026-11-03MURPHY ANDREW JSell1.05K——
2026-11-03Zoghbi Huda YBuy7.44K$380.952.83M
2026-11-03Zoghbi Huda YSell6.94K$970.426.73M
2026-11-03Zoghbi Huda YSell500$971.06485.53K
2026-11-03Zoghbi Huda YSell7.44K$380.952.83M
2026-11-02SING GEORGE LBuy7.44K$380.952.83M
2026-11-02SING GEORGE LSell1.22K$960.571.18M
2026-11-02SING GEORGE LSell540$961.85519.40K
2026-11-02SING GEORGE LSell2.52K$962.612.43M
2026-11-02SING GEORGE LBuy7.83K$376.692.95M
2026-11-02SING GEORGE LSell4.34K$963.474.18M
2026-11-02SING GEORGE LSell2.67K$964.572.58M
2026-11-02SING GEORGE LSell7.07K$965.386.83M
2026-11-02SING GEORGE LSell1.52K$966.271.47M
2026-11-02SING GEORGE LSell1.04K$967.071.01M
2026-11-02SING GEORGE LSell200$970.18194.04K
2026-11-02SING GEORGE LSell7.83K$376.692.95M
2026-11-02SING GEORGE LSell7.44K$380.952.83M
2026-11-02POON CHRISTINE ABuy7.83K$376.692.95M
2026-11-02POON CHRISTINE ASell218$966.74210.75K
2026-11-02POON CHRISTINE ASell772$967.38746.82K
2026-11-02POON CHRISTINE ASell2.50K$968.582.42M
2026-11-02POON CHRISTINE ASell3.20K$969.503.11M
2026-11-02POON CHRISTINE ASell937$970.51909.37K
2026-11-02POON CHRISTINE ASell201$971.31195.23K
2026-11-02POON CHRISTINE ASell7.83K$376.692.95M
2026-11-02Fenimore Christopher R.Buy6.00K$381.922.29M
2026-11-02Fenimore Christopher R.Sell4.24K$950.504.03M
2026-11-02Fenimore Christopher R.Sell15——
2026-11-02Fenimore Christopher R.Sell6.00K$381.922.29M
2026-11-02LAROSA JOSEPH JBuy12.28K$381.924.69M
2026-11-02LAROSA JOSEPH JSell8.69K$950.508.26M
2026-11-02LAROSA JOSEPH JSell3.94K$965.413.80M
2026-11-02LAROSA JOSEPH JSell527$966.11509.14K
2026-11-02LAROSA JOSEPH JSell12.28K$381.924.69M
2026-10-30Guarini KathrynBuy400$719.37287.75K
2026-10-30Guarini KathrynSell400$719.37287.75K
2026-10-30Guarini KathrynSell400$900.00360.00K
2026-10-30BROWN MICHAEL SBuy1.93K$725.891.40M
2026-10-30BROWN MICHAEL SSell1.93K$875.001.69M
2026-10-30BROWN MICHAEL SSell1.93K$725.891.40M
2026-10-30McCourt MarionSell1.13K$869.43984.19K
2026-10-14MURPHY ANDREW JSell6$753.764.52K
2026-10-14MURPHY ANDREW JSell35$755.9126.46K
2026-10-14MURPHY ANDREW JSell16$757.6812.12K
2026-10-14MURPHY ANDREW JSell24$758.1618.20K
2026-10-14MURPHY ANDREW JSell14$759.9610.64K
2026-10-14MURPHY ANDREW JSell74$760.6556.29K
2026-10-14MURPHY ANDREW JSell27$761.3620.56K
2026-10-14MURPHY ANDREW JSell55$762.5741.94K
2026-10-14MURPHY ANDREW JSell25$763.7619.09K
2026-10-14MURPHY ANDREW JSell219$764.40167.40K
2026-10-14MURPHY ANDREW JSell271$765.39207.42K
2026-10-14MURPHY ANDREW JSell279$766.47213.85K
2026-10-14MURPHY ANDREW JSell192$767.39147.34K
2026-10-14MURPHY ANDREW JSell105$768.3380.67K
2026-10-14MURPHY ANDREW JSell127$769.3097.70K
2026-10-14MURPHY ANDREW JSell12$770.209.24K
2026-10-14MURPHY ANDREW JSell283$771.56218.35K
2026-10-14MURPHY ANDREW JSell211$772.56163.01K
2026-10-14MURPHY ANDREW JSell224$773.40173.24K
2026-10-14MURPHY ANDREW JSell121$774.4893.71K
2026-10-14MURPHY ANDREW JSell376$775.46291.57K
2026-10-14MURPHY ANDREW JSell66$776.3151.24K
2026-10-14MURPHY ANDREW JSell38$777.7629.55K
2026-10-14MURPHY ANDREW JSell454$778.64353.50K
2026-10-14MURPHY ANDREW JSell380$779.59296.24K
2026-10-14MURPHY ANDREW JSell463$780.63361.43K
2026-10-14MURPHY ANDREW JSell50$781.4739.07K
2026-10-13MURPHY ANDREW JBuy17.00K$381.926.49M
2026-10-13MURPHY ANDREW JSell12.85K$754.589.70M
2026-10-13MURPHY ANDREW JSell17.00K$381.926.49M
2026-09-03McCourt MarionSell1.13K$857.39969.71K
2026-09-02McCourt MarionSell1.22K$850.001.03M
2026-09-02Guarini KathrynSell400$719.37287.75K
2026-09-02Guarini KathrynBuy400$719.37287.75K
2026-09-02Guarini KathrynSell400$850.00340.00K
2026-08-19LAROSA JOSEPH JBuy12.28K$381.924.69M
2026-08-19LAROSA JOSEPH JSell9.02K$830.157.49M
2026-08-19LAROSA JOSEPH JSell12.28K$381.924.69M
2026-08-18Fenimore Christopher R.Buy6.28K$381.922.40M
2026-08-18Fenimore Christopher R.Sell4.60K$813.473.74M
2026-08-18Fenimore Christopher R.Sell6.28K$381.922.40M
2026-08-10Guarini KathrynSell400$719.37287.75K
2026-08-10Guarini KathrynBuy400$719.37287.75K
2026-08-10Guarini KathrynSell400$800.00320.00K

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 1.40K, holders -67 vs prior quarter. Ownership 89.28%.

HolderSharesChangeChange %Value
BLACKROCK, INC.9.11M165.77K+1.85%5.68B
VANGUARD CAPITAL MANAGEMENT LLC6.63M-25.15K-0.38%4.13B
DODGE & COX4.87M412.90K+9.26%3.04B
STATE STREET CORP4.83M170.21K+3.65%3.01B
INVESCO LTD.3.94M1.76M+80.71%2.46B
JPMORGAN CHASE & CO3.77M-537.61K-12.47%2.38B
VANGUARD PORTFOLIO MANAGEMENT LLC3.18M1.45M+84.53%1.98B
FRANKLIN TEMPLETON INC2.77M49.77K+1.83%1.73B
GEODE CAPITAL MANAGEMENT, LLC2.63M18.08K+0.69%1.63B
NUVEEN, LLC2.02M-45.09K-2.18%1.26B
LOOMIS SAYLES & CO L P1.86M-53.14K-2.78%1.16B
PRICE T ROWE ASSOCIATES INC /MD/1.53M-647.82K-29.75%953.84M
MORGAN STANLEY1.40M78.38K+5.94%871.53M
BANK OF AMERICA CORP /DE/1.29M101.47K+8.53%805.02M
WELLINGTON MANAGEMENT GROUP LLP1.27M-567.37K-30.88%791.95M
NORGES BANK1.17M1.17MNew731.29M
GOLDMAN SACHS GROUP INC1.16M975.59K+520.04%725.30M
AQR CAPITAL MANAGEMENT LLC1.13M-104.93K-8.52%702.16M
AMUNDI1.01M3.74K+0.37%631.98M
NORTHERN TRUST CORP916.47K-25.47K-2.70%571.45M
CHARLES SCHWAB INVESTMENT MANAGEMENT INC846.31K41.80K+5.20%527.71M
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.846.31K846.31KNew527.71M
FMR LLC831.96K-686.23K-45.20%518.76M
CAPITAL WORLD INVESTORS814.92K-604.08K-42.57%508.14M
LEGAL & GENERAL GROUP PLC759.97K27.92K+3.81%473.87M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener